大行评级｜中银国际：信达生物近期披露差异化资产的积极数据上调目标价至56港元

格隆汇资讯07-09

中银国际发表报告指，信达生物最近披露差异化资产的积极数据，包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。此外，公司的两项资产IBI112和IBI311均具有可观的市场潜力，已分别临近和进入新药上市评审阶段。报告指，信达生物已上市的产品组合，比如PD-1，VEGF，PCSK9，TNF-α，分别针对肿瘤、心血管及代谢，以及自身免疫领域的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450013094?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-09 17:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2450013094","market":"hk","top_or_hot":-1,"title":"大行评级｜中银国际：信达生物近期披露差异化资产的积极数据 上调目标价至56港元","media":"格隆汇资讯","content":"<div>\n<p>中银国际发表报告指，信达生物最近披露差异化资产的积极数据，包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。此外，公司的两项资产IBI112和IBI311均具有可观的市场潜力，已分别临近和进入新药上市评审阶段。报告指，信达生物已上市的产品组合，比如PD-1，VEGF，PCSK9，TNF-α，分别针对肿瘤、心血管及代谢，以及自身免疫领域的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大行评级｜中银国际：信达生物近期披露差异化资产的积极数据 上调目标价至56港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大行评级｜中银国际：信达生物近期披露差异化资产的积极数据 上调目标价至56港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-09 17:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中银国际发表报告指，信达生物最近披露差异化资产的积极数据，包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。此外，公司的两项资产IBI112和IBI311均具有可观的市场潜力，已分别临近和进入新药上市评审阶段。报告指，信达生物已上市的产品组合，比如PD-1，VEGF，PCSK9，TNF-α，分别针对肿瘤、心血管及代谢，以及自身免疫领域的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b","article_id":"2450013094","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2450013094","pubTimestamp":1720516169,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中银国际发表报告指，信达生物最近披露差异化资产的积极数据，包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。报告指，信达生物已上市的产品组合，比如PD-1，VEGF，PCSK9，TNF-α，分别针对肿瘤、心血管及代谢，以及自身免疫领域的大量患者群体，信达有望利用这些治疗领域内的协同效应，将新产品组合更好更快的推向市场。该行维持信达生物“买入”评级，并根据近期研发管线进展，将目标价上调至56港元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01801":"信达生物"},"translate_title":"Big Bank Ratings | BOC International: Cinda Biologics recently disclosed positive data on differentiated assets and raised its target price to HK $56","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"中银国际发表报告指，信达生物最近披露差异化资产的积极数据，包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。此外，公司的两项资产IBI112和IBI311均具有可观的市场潜力，已分别临近和进入新药上市评审阶段。报告指，信达生物已上市的产品组合，比如PD-1，VEGF，PCSK9，TNF-α，分别针对肿瘤、心血管及代谢，以及自身免疫领域的大量患者群体，信达有望利用这些治疗领域内的协同效应，将新产品组合更好更快的推向市场。信达似乎正在从生物技术公司向生物制药公司转型。虽然该行认可公司在临床和注册方面的强大执行力，但将密切关注其商业化能力，这是其成功转型的关键指标，尤其是考虑到目前肿瘤之外的商业化团队尚未成熟。该行维持信达生物“买入”评级，并根据近期研发管线进展，将目标价上调至56港元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450013094"}

大行评级｜中银国际：信达生物近期披露差异化资产的积极数据 上调目标价至56港元

精彩评论

大行评级｜中银国际：信达生物近期披露差异化资产的积极数据上调目标价至56港元